de los Santos-Jiménez, Juan
Campos-Sandoval, José A.
Márquez-Torres, Clara
Urbano-Polo, Nieves
Brøndegaard, David
Martín-Rufián, Mercedes
Lobo, Carolina
Peñalver, Ana
Gómez-García, María C.
Martín-Campos, Janet
Cardona, Carolina
Castilla, Laura
da Costa Souza, Felipe
Cheng, Tzuling
Segura, Juan A.
Alonso, Francisco J.
Curi, Rui
Colquhoun, Alison
DeBerardinis, Ralph J.
Márquez, Javier
Matés, José M. http://orcid.org/0000-0001-9795-1993
Funding for this research was provided by:
Ministerio de Ciencia y Tecnología (RTI2018-096866-B-I00)
Ministerio de Ciencia y Tecnología (RTI2018-096866-B-I00)
Howard Hughes Medical Institute
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Cancer Prevention and Research Institute of Texas
Moody's Foundation
CAPES (CAPES/DGU 250/11)
Ministerio de Ciencia, Innovación y Universidades (FPU17/04084)
Article History
Received: 3 October 2020
Accepted: 5 February 2021
First Online: 20 February 2021
Ethics approval and consent to participate
: Not applicable since no patients subjects were used in this study.
: Not applicable. All authors read and approved the manuscript.
: RJD is an advisor for Agios Pharmaceuticals.